Delivery Order SPE2DR25D2205-SPE2DR26F1K48
- Not listed
- The Defense Logistics Agency awarded a $11,017.75 delivery order to AmerisourceBergen Drug Corp for the supply of Taltz 80 mg/ml autoinjector on December 11, 2025, with completion scheduled for December 12, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $30,520.46 to supply Taltz 80 mg/ml autoinjectors. The award was made on November 28, 2025, with an ultimate completion date of December 1, 2025, under a firm fixed-price contract type with no set-aside designation. The contract will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $4,580.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/mL autoinjectors, with an ultimate completion date of October 30, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be supplied to the place of...
- The Defense Logistics Agency awarded a $18,969.16 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml auto-injector medication on December 9, 2025, with completion scheduled for December 10, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a $39,167.67 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml auto-injector (2-pack) pharmaceutical products on October 22, 2025, with completion targeted for October 23, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded procurement supporting federal medical supply requirements. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $46,054.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Taltz 80 mg/mL auto-injector (2-pack) pharmaceutical product. The contract, which is set to be completed by August 1, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This competitively awarded delivery order represents a continuation of AmerisourceBergen's ongoing role as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a $31,833.56 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/mL auto-injector (2-pack) pharmaceutical products, with an ultimate completion date of July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $7,760.84 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml auto-injector units, with an ultimate completion date of October 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $12,688.26 to AmerisourceBergen Drug Corp for the supply of Taltz 80 mg/ml auto-injectors, with a firm fixed price structure and an ultimate completion date of May 28, 2025. This non-competitive delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999 and extends through December 2026. The contract...
- The Defense Logistics Agency awarded a delivery order valued at $26,509.75 to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml auto-injector on November 20, 2025, with an ultimate completion date of November 21, 2025. This competitively awarded, firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract utilizes no set-aside designation and...
- SPE2DR25D2205Indefinite Delivery Contract
- SPE2DR25D2205-SPE2DR26F1K48Delivery Order
The Defense Logistics Agency awarded a $80,176.82 delivery order to AmerisourceBergen Drug Corp for Taltz 80 mg/ml auto-injectors (2-pack) with a completion date of November 26, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. The delivery order will be fulfilled from the company's Conshohocken location. This delivery order is issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The parent IDC functions as a global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. Taltz (ixekizumab) is a biologic immunosuppressant used to treat autoimmune conditions, and this order supports the Defense Health Agency's pharmaceutical supply requirements within the broader medical supply chain supporting U.S. military personnel and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $80.2k | 11/24/25 |